I have been a shareholder for a couple of years, but have never done the due diligence that one should with any company. The prospects seem thrilling, but I decided to try to think of potential problems. If another pharmaceutical company found a way to synthesise in the lab the part that comes from beech trees, that would almost certainly be cheaper, and would be significant competition. Would any of the holders who have researched it a lot be kind enough to comment.
The novel drug - A DMOAD approach, page-19
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.0¢ | 21.5¢ | $78.13K | 350.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 64880 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 43479 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |